SK5202Y1 - Sustained release dosage form for peroral administration - Google Patents

Sustained release dosage form for peroral administration Download PDF

Info

Publication number
SK5202Y1
SK5202Y1 SK5057-2006U SK50572006U SK5202Y1 SK 5202 Y1 SK5202 Y1 SK 5202Y1 SK 50572006 U SK50572006 U SK 50572006U SK 5202 Y1 SK5202 Y1 SK 5202Y1
Authority
SK
Slovakia
Prior art keywords
dosage form
sustained release
opioid
oral dosage
drug
Prior art date
Application number
SK5057-2006U
Other languages
English (en)
Slovak (sk)
Other versions
SK50572006U1 (en
Inventor
Gayatri Sathyan
Nipun Davar
Linda Hearney Pors
Gemma Casadevall
Jayne Hastedt
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of SK50572006U1 publication Critical patent/SK50572006U1/sk
Publication of SK5202Y1 publication Critical patent/SK5202Y1/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SK5057-2006U 2005-10-31 2006-07-13 Sustained release dosage form for peroral administration SK5202Y1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73199505P 2005-10-31 2005-10-31
US80201706P 2006-05-18 2006-05-18

Publications (2)

Publication Number Publication Date
SK50572006U1 SK50572006U1 (en) 2009-01-07
SK5202Y1 true SK5202Y1 (en) 2009-06-05

Family

ID=36758362

Family Applications (1)

Application Number Title Priority Date Filing Date
SK5057-2006U SK5202Y1 (en) 2005-10-31 2006-07-13 Sustained release dosage form for peroral administration

Country Status (11)

Country Link
BG (1) BG1070U1 (sv)
CA (6) CA2554684A1 (sv)
CZ (1) CZ19137U1 (sv)
DK (1) DK200600189U3 (sv)
FI (1) FI7357U1 (sv)
GB (1) GB0612326D0 (sv)
IE (1) IES20060507A2 (sv)
NL (1) NL1032148C1 (sv)
NO (1) NO20063233L (sv)
SE (1) SE0601589L (sv)
SK (1) SK5202Y1 (sv)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2692437T3 (es) 2007-08-13 2018-12-03 Abuse Deterrent Pharmaceutical Llc Fármacos resistentes al abuso, método de uso y método de preparación
US20140275149A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US10172842B2 (en) * 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine

Also Published As

Publication number Publication date
GB0612326D0 (en) 2006-08-02
CA2554874A1 (en) 2007-04-30
CZ19137U1 (cs) 2008-12-08
CA2554693A1 (en) 2007-04-30
DK200600189U3 (da) 2007-02-23
FI7357U1 (sv) 2007-01-16
BG1070U1 (bg) 2008-06-30
SK50572006U1 (en) 2009-01-07
IES20060507A2 (en) 2007-05-30
FIU20060296U0 (sv) 2006-07-12
CA2554684A1 (en) 2007-04-30
NO20063233L (no) 2007-05-02
CA2554697A1 (en) 2007-04-30
CA2554701A1 (en) 2007-04-30
SE0601589L (sv) 2007-05-01
NL1032148C1 (nl) 2006-11-17
CA2554698A1 (en) 2007-04-30

Similar Documents

Publication Publication Date Title
CZ17801U1 (cs) Perorální aplikacní forma s prodlouženým uvolnováním opioidu
US20040091529A1 (en) Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
US20110195981A1 (en) Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20060189635A1 (en) Enhanced efficacy benzisoxazole derivative dosage forms and methods
CA2613933A1 (en) Methods and dosage forms for reducing side effects of carbamate compounds
WO2006085856A1 (en) Methods and dosage forms for reducing side effects of benzisozazole derivatives
EP1849460A2 (en) Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
SK5202Y1 (en) Sustained release dosage form for peroral administration
ITTO20060161U1 (it) Procedimenti per ridurre il rilascio precipitoso indotto da alcool per forme di dosaggio orali a rilascio prolungato di oppioidi
ITTO20060112U1 (it) Procedimenti per ridurre il rilascio precipitoso indotto da alcool per forme di dosaggio orali a rilascio prolungato di oppioidi.
IES84730Y1 (en) Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms